Ex-PM Boris Johnson deliberately misled UK parliament over parties during Covid, committee rules

Ex-PM Boris Johnson deliberately misled UK parliament over parties during Covid, committee rules


A U.K. parliamentary committee has found that former U.K. prime minister Boris Johnson intentionally misled parliament over illegal Covid-19 lockdown parties held during his tenure.

Carl Court | Getty Images News | Getty Images

Former U.K. prime minister Boris Johnson intentionally misled parliament over illegal Covid-19 lockdown parties held during his tenure, a parliamentary committee said Thursday, dubbing the act as a “serious contempt.”

The damning verdict of the privilege committee’s long-awaited “partygate” report found that Johnson had willfully deceived parliament several times when probed about Downing Street parties that occurred under his watch and broke his own lockdown rules.

“We conclude that in deliberately misleading the House, Mr Johnson committed a serious contempt,” the findings of the cross-party committee showed.

“There is no precedent for a Prime Minister having been found to have deliberately misled the House,” it added.

The 100-page report, which investigated six gatherings held at the prime minister’s official residence at the time of the U.K.’s most stringent Covid restrictions, also concluded that Johnson was complicit in a “campaign of abuse and attempted intimidation” to disguise the circumstances of those events.

The committee, which consists of members of both the ruling Conservative Party and opposition Labour Party, recommended that Johnson should not be entitled to a former Member’s pass, which allows former prime ministers to access parliament.

It also said that, if Johnson were still a member of parliament, he should be suspended from the House for 90 days. Johnson resigned as a Conservative MP last week after seeing an advanced copy of the report. At the time, he accused the cross-party committee of behaving like a “kangaroo court” conducting a “political hit job” against him.

In a further statement Thursday, he dubbed the findings “rubbish,” “absurd” and “deranged,” according to Perspective magazine and the Telegraph. The ex-prime minister, a fervent Brexiteer, also accused the committee of “prejudicial views,” saying that a majority of members “voted remain” in the 2016 Brexit vote.

“The committee now says that I deliberately misled the House, and at the moment I spoke I was consciously concealing from the House my knowledge of illicit events,” he wrote.

“This is rubbish. It is a lie. In order to reach this deranged conclusion, the committee is obliged to say a series of things that are patently absurd, or contradicted by the fact.”

MPs responsible for producing the report described Johnson’s comments as a blow against U.K. democratic institutions.

“This attack on a committee carrying out its remit from the democratically elected House itself amounts to an attack on our democratic institutions,” the committee said.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More